SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs Healthcare
Conference on Thursday, June 14, 2007 at 9:20 a.m. PT in Laguna Nigel, CA.
Daniel M. Bradbury, President and Chief Executive Officer of Amylin
Pharmaceuticals, will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through Amylin's corporate website, located at http://www.amylin.com. To
access the live webcast, please log on to Amylin's site approximately
fifteen minutes prior to the presentation to register and download any
necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,600 employees nationwide. For
more information about Amylin visit http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com/
CONTACT:
Alice Bahner Izzo, Executive Director,
Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200, ext. 7272
|
